Aptose Biosciences, Inc.
APTO
APTO: Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
moreShow APTO Financials
Recent trades of APTO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by APTO's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Fused pyrimidine compounds as brd4 and jak2 dual inhibitors and methods for use thereof Mar. 22, 2022
-
Patent Title: Aryl imidazoles for treatment of cancer Oct. 19, 2021
-
Patent Title: Compositions and methods for treating cancers Aug. 31, 2021
-
Patent Title: Aryl imidazoles and their use as anti-cancer agents Sep. 25, 2018
-
Patent Title: Compositions and methods for treating cancers Feb. 14, 2017
-
Patent Title: 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents Mar. 24, 2015
Federal grants, loans, and purchases
Followers on APTO's company Twitter account
Number of mentions of APTO in WallStreetBets Daily Discussion
Recent insights relating to APTO
Recent picks made for APTO stock on CNBC
ETFs with the largest estimated holdings in APTO
Flights by private jets registered to APTO